Ubicación: Global + English
Global Global Algérie Français Algeria English Angola Português Angola English Argentina Español Argentina English Australia English Austria Deutsch Austria English Azerbaijan English Azerbaijan Русский Bahrain English Bangladesh English Belgium English Belgium Français Belgium Nederlands Brazil Português Brazil English Bulgaria български Bulgaria English Cameroon English Cameroon Français Canada English Canada Français Chile Español Chile English China 中文 China 日本語 China English Colombia Español Colombia English Croatia English Czech Republic Čeština Czech Republic English Denmark English Djibouti English Ecuador Español Ecuador English Egypt English Estonia English Ethiopia English Finland Suomi Finland English France Français France English Georgia English Georgia Русский Germany Deutsch Germany English Ghana English Greece Ελληνικά Greece English Guatemala Español Guatemala English Hong Kong, China English Hong Kong, China 中文 Hungary Magyar Hungary English India English Indonesia English Iraq English Ireland English Italy Italiano Italy English Ivory Coast Français Ivory Coast English Japan 日本語 Japan English Jordan English Kazakhstan Русский Kazakhstan English Kenya English Kuwait English Kyrgyzstan Русский Kyrgyzstan English Latvia English Lithuania English Malaysia English Mauritius English Mauritius français (Maurice) Mexico Español Mexico English Moldova Română Moldova English Mongolia English Morocco English Morocco Français Mozambique Português Mozambique English Netherlands Nederlands Netherlands English New Zealand English Nigeria English Norway English Oman English Pakistan English Paraguay Español Paraguay English Peru Español Peru English Philippines English Poland Polski Poland English Portugal Português Portugal English Qatar English Republic of Korea 한국어 Republic of Korea English Romania Română Romania English Saudi Arabia English Serbia Српски Serbia English Singapore English Slovakia English Slovenia English South Africa English Spain English Spain Español Sri Lanka English Sweden English Switzerland Deutsch Switzerland Français Switzerland Italiano Switzerland English Tanzania English Thailand ไทย Thailand English Togo English Togo Français Tunisia English Tunisia Français Türkiye Türkçe Türkiye English Turkmenistan Русский Turkmenistan English Ukraine Українська Ukraine English United Arab Emirates English United Kingdom English Uruguay Español Uruguay English USA English Uzbekistan English Uzbekistan Русский Vietnam Tiếng Việt Vietnam English

The Novel Object Recognition Test (NORT) is one of the most widely used behavioral assays for evaluating recognition memory in rodents, relying on the natural tendency of animals to explore unfamiliar objects more than familiar ones. This article provides a comprehensive technical overview of the test principle, suitable animal models, key testing parameters, standardized experimental procedures, and its broad applications in neuroscience research and pharmaceutical development. Researchers and laboratory professionals will find practical guidance on protocol design, scoring metrics, and quality controls for generating reliable, reproducible cognition data.

Technical Overview

The Novel Object Recognition Test (NORT), also known as the Novel Object Recognition paradigm, is a spontaneous behavioral assay designed to evaluate recognition memory and exploratory behavior in rodents. First introduced by Ennaceur and Delacour in 1988, the test is based on the innate preference of rodents to spend more time investigating a novel object than a previously encountered familiar one, without the need for external rewards, food deprivation, or aversive stimuli.

Because the task requires no extensive training and imposes minimal stress on the subjects, it avoids many of the confounding factors associated with motivation- and reinforcement-based memory tests such as the Morris water maze or passive avoidance. Recognition performance is quantified through objective exploration-time metrics, making the test highly suitable for high-throughput pharmacological screening, neurotoxicity assessment, and cognitive phenotyping of transgenic models.

Key advantages of the Novel Object Recognition experiment include:

  • No requirement for food or water restriction, reducing metabolic and stress-related confounds
  • Short experimental timeline, typically completed within two to four days per cohort
  • Sensitivity to multiple memory phases, including acquisition, consolidation, and retrieval
  • Applicability to both short-term memory (minutes to hours) and long-term memory (24 hours or more)
  • Compatibility with automated video-tracking systems for unbiased, high-resolution data capture

Testing Samples

Rodent Species and Strains

The Novel Object Recognition Test is routinely performed on laboratory mice and rats. Commonly used mouse strains include C57BL/6J, BALB/c, and ICR (CD-1), while frequently used rat strains include Sprague-Dawley, Wistar, and Long-Evans. Subjects are typically 8 to 12 weeks of age at the time of testing, although aged animals (12 months and older) are frequently included in studies of cognitive decline. A minimum of 10 to 15 animals per group is recommended to achieve adequate statistical power.

Transgenic and Disease Models

The test is extensively applied to cognitive phenotyping of genetically modified and chemically induced disease models, including:

  • Alzheimer's disease transgenic lines such as APP/PS1, 5xFAD, and 3xTg-AD mice
  • Scopolamine- or MK-801-induced amnesia models for pharmacological validation
  • Amyloid-beta or tau infusion models of neurodegeneration
  • Cerebral ischemia, traumatic brain injury, and epilepsy models with comorbid memory impairment
  • Naturally aged animals for senescence-associated cognitive decline studies

Housing and Pre-Experimental Conditions

Animals should be maintained under a standard 12-hour light/dark cycle at controlled temperature (20 to 24 degrees Celsius) and humidity (40 to 70 percent), with ad libitum access to food and water. A minimum acclimation period of seven days in the testing facility is required, followed by two to three days of gentle handling by the experimenter. Testing should be conducted at a consistent time of day to minimize circadian variability, ideally during the animals' active phase when exploratory drive is highest.

Testing Items

The core quantitative endpoints of the Novel Object Recognition experiment are summarized below:

  • Exploration time of the familiar object during the test trial (T_familiar)
  • Exploration time of the novel object during the test trial (T_novel)
  • Discrimination Index (DI), calculated as DI = (T_novel minus T_familiar) / (T_novel plus T_familiar)
  • Recognition index or preference ratio, expressed as the percentage of total exploration time directed toward the novel object
  • Total exploration time, used to assess baseline exploratory activity and exclude underperforming subjects
  • Locomotor parameters such as total distance traveled and mean velocity, collected as covariates to rule out motor or sedative effects
  • Memory phase-specific endpoints, differentiating short-term memory (tested at 1 to 2 hour retention intervals) from long-term memory (tested at 24 hours or longer)

A Discrimination Index significantly greater than zero indicates intact recognition memory, whereas performance near zero suggests memory impairment. Performance below zero, indicating a paradoxical preference for the familiar object, warrants review of object counterbalancing and olfactory cue control.

Testing Methods

The standard protocol consists of three sequential phases conducted in an open-field arena, commonly 40 x 40 x 40 cm for mice and 70 to 100 cm square for rats, illuminated uniformly at approximately 20 to 30 lux at floor level and monitored by an overhead camera linked to video-tracking software.

Phase 1: Habituation. Each animal is placed in the empty arena and allowed to freely explore for 5 to 10 minutes on one or two consecutive days to reduce neophobia toward the testing environment.

Phase 2: Familiarization (T1). Two identical objects are positioned in symmetrically opposite corners of the arena. The animal explores for 3 to 10 minutes, with a common inclusion criterion of at least 20 to 30 seconds of cumulative object exploration.

Phase 3: Test Trial (T2). After a defined inter-trial interval, one familiar object is replaced with a novel object differing in shape, texture, or color but similar in size and complexity. The animal explores for 3 to 5 minutes while the session is recorded for offline or automated scoring. Objects are constructed from inert, cleanable materials such as glass, ceramic, or metal, are sufficiently heavy to prevent displacement, and are sanitized with 70 percent ethanol between trials to eliminate residual olfactory cues.

Exploration is operationally defined as directing the nose toward the object at a distance of less than 2 cm, or touching the object with the nose or vibrissae. Climbing on, sitting on, or rearing against the object is excluded from scoring. Object placement (left versus right) and object identity (familiar versus novel) are counterbalanced across subjects to control for positional bias.

Quality control measures include:

  • Exclusion of animals with total exploration below 10 seconds in either trial
  • Blinded manual scoring or validated automated detection to eliminate observer bias
  • Two-way analysis of variance or paired t-tests for within-group novel versus familiar comparisons
  • A priori sample size estimation based on power analysis
  • Data reporting in accordance with the ARRIVE guidelines, ideally conducted in GLP-compliant or accredited third-party laboratory facilities

Applications

The Novel Object Recognition Test supports a wide range of preclinical research and development activities:

  • Pharmacological screening: Evaluation of cognitive enhancers including acetylcholinesterase inhibitors, NMDA receptor modulators, phosphodiesterase inhibitors, and plant-derived bioactive extracts, using scopolamine-induced amnesia as a reversible deficit model
  • Neurodegenerative disease research: Longitudinal characterization of memory decline in amyloid and tau pathology models, and assessment of disease-modifying interventions
  • Safety pharmacology and neurotoxicology: Screening for cognitive side effects of developmental compounds, anesthetics, heavy metals, pesticides, and environmental pollutants, in the spirit of ICH S7A safety pharmacology principles and OECD neurotoxicity testing guidance
  • CNS injury studies: Quantification of memory deficits and recovery following traumatic brain injury, stroke, and status epilepticus
  • Aging and developmental neurotoxicity: Assessment of cognitive changes across the lifespan and following early-life chemical exposures
  • Basic neuroscience: Functional investigation of the perirhinal cortex, hippocampus, and related circuits underlying recognition memory and synaptic plasticity

FAQ

Q1: What is the difference between the Novel Object Recognition Test and the Object Location Test?

The Novel Object Recognition Test evaluates object identity memory by substituting a familiar object with a novel one and relies primarily on perirhinal cortex function. The Object Location Test instead relocates a familiar object to a new position, probing spatial memory associated with hippocampal function. The two assays are frequently combined to dissociate non-spatial from spatial memory components.

Q2: Which retention interval should be used?

Retention intervals of 1 to 2 hours are standard for short-term memory assessment, while 24-hour intervals probe long-term memory consolidation. Intermediate intervals such as 3 to 4 hours can be selected to resolve subtle deficits, and the interval should be fixed across an entire study for comparability.

Q3: Why might animals show no preference for the novel object?

Common causes include insufficient habituation, object preference bias, residual olfactory cues, low lighting-induced anxiety, sedative or stimulant treatment effects on locomotion, or a genuine memory deficit. Systematic counterbalancing, adequate exploration criteria, and locomotor covariate analysis are essential for correct interpretation.

Q4: Are there recognized standards governing this experiment?

There is no single ISO or IEC method standard dedicated to this behavioral assay; however, studies are expected to follow OECD principles of good laboratory practice where regulatory submission is intended, ICH S7A concepts for safety pharmacology relevance, and ARRIVE reporting guidelines for animal research rigor. Collaborating with accredited third-party laboratories ensures protocol standardization and data integrity.

Q5: Can the test be automated?

Yes. Overhead cameras combined with commercially available video-tracking software enable automated measurement of exploration time, movement trajectories, and velocity, substantially reducing scoring workload and inter-observer variability while supporting high-throughput cohort testing.